TITLE

SEN virus infection in patients with chronic liver disease and hepatocellular carcinoma in Thailand

AUTHOR(S)
Tangkijvanich, Pisit; Theamboonlers, Apiradee; Sriponthong, Maturapod; Thong-Ngam, Duangporn; Kullavanijaya, Pinit; Poovorawan, Yong
PUB. DATE
February 2003
SOURCE
Journal of Gastroenterology;2003, Vol. 38 Issue 2, p142
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background SEN virus (SENV) has been recently identified as a candidate agent of non-A-E hepatitis virus. However, the exact role of this novel virus in the pathogenesis of chronic liver disease, including chronic hepatitis and cirrhosis, and the development of hepatocellular carcinoma (HCC) remains to be established. Methods. Using seminested polymerase chain reaction (PCR) amplification to detect SENV-D and SENV-H strains in serum, we investigated SENV infection in voluntary blood donors and in patients with chronic liver disease and HCC. Results. SENV was detected in 5 of 100 blood donors (5%), in 15 of 60 patients with chronic liver disease (25%), and in 25 of 60 patients with HCC (42%). The prevalence of SENV in patients with HCC was higher than that in patients with chronic liver disease (P = 0.05) and in blood donors (P < 0.001). An age-specific prevalence of SENV was found at high levels among individuals aged 21-40 years, but was not detected among individuals in the lower age group. No differences between SENV-infected and non-infected patients were demonstrated with respect to demographic data, assumed source of infection, biochemical abnormalities, and severity of chronic liver disease and HCC. Moreover, SENV infection had no apparent effect on the survival of patients with HCC. Conclusions. Our data suggest that SENV infection is frequent among patients with chronic liver disease and HCC. However, pathogenic effects associated with SENV infection in chronic liver disease and HCC need further investigation.
ACCESSION #
9309612

 

Related Articles

  • Identification of a novel 23 kDa protein encoded by putative open reading frame 2 of TT virus (TTV) genotype 1 different from the other genotypes. Tanaka, Y.; Orito, E.; Ohno, T.; Nakano, T.; Hayashi, K.; Kato, T.; Mukaide, M.; Iida, S.; Mizokami, M. // Archives of Virology;Jul2000, Vol. 145 Issue 7, p1385 

    Summary. We report the entire open reading frames (ORFs) sequences of four TT virus (TTV) isolates, one genotype 2 (G2) and three G4 isolates. Despite a DNA virus, TTV possesses high rate of amino acid (aa) substitution: the aa sequence homology of ORF1 and 2 is lower than the nucleotide...

  • Desperately seeking hepatitis C virus. Moreno-Otero, Ricardo; Tarantino, Giovanni; Lakatos, Peter L.; Nakajima, Hisato // World Journal of Gastroenterology;5/14/2008, Vol. 14 Issue 18, p2946 

    Spanish investigators described recently the so-called occult hepatitis C virus (HCV) infection, emphasizing the detection of genomic and antigenomic HCV RNA strands in liver and peripheral blood mononuclear cells. Therefore, the persistence of viral replication in occult HCV infection should be...

  • Hepatocarcinogenesis in hepatitis viral infection: lessons from transgenic mouse studies. Koike, Kazuhiko // Journal of Gastroenterology;2002 Supplement 13, Vol. 37, p55 

    Over the past decade, genetically engineered mouse models have been used for studies of the mechanisms underlying human diseases. One advantage of these models is that the targeted protein executes its function in normal cells in their natural tissue microenvironments. Transgenic mouse models...

  • Modulation of RANTES expression by HCV core protein in liver derived cell lines. Ruggieri, Anna; Franco, Marina; Gatto, Ilaria; Kumar, Ajit; Rapicetta, Maria // BMC Gastroenterology;2007, Vol. 7, p21 

    Background: Hepatitis C virus (HCV) infection is associated with high percentage of chronicity which implies the ability of the virus to evade or modulate host cell immune system. Modulation of chemokines, such as RANTES may be part of the virus induced pathogenicity. We examined the effect of...

  • Clinical Implications of TT Virus Superinfection in Patients With Chronic Hepatitis C. Watanabe, Hisayoshi; Saito, Takafumi; Kawamata, Osamu; Li Shao; Aoki, Masanori; Terui, Yuki; Mitsuhashi, Hideki; Matsuo, Taku; Takeda, Yoshio; Saito, Koji; Togashi, Hitoshi; Shinzawa, Haruhide; Takahashi, Tsuneo // American Journal of Gastroenterology;Jul2000, Vol. 95 Issue 7, p1776 

    OBJECTIVE: TT virus (TTV) has been identified as a candidate agent of non-A-E hepatitis virus. We investigated superinfection of TTV in patients with chronic hepatitis C and studied the susceptibility to interferon (IFN) treatment and its association with liver disease caused by hepatitis C...

  • Getting hip on hep: A review of viral hepatitis. Inge, Lisa; Seiha Kim // Drug Topics;4/3/2006, Vol. 150 Issue 7, p35 

    The article examines the cases of acute viral hepatitis in the U.S. Viral hepatitis refers to liver disease caused by hepatotropic viruses, in which signs and symptoms of hepatitis are secondary to inflammation and necrosis of the liver. The documented hepatotropic viruses include hepatitis A...

  • Clear on infection. Gallacher, Rose // Nursing Standard;4/7/2004, Vol. 18 Issue 30, p22 

    Discusses the nature of hepatitis transmission. Transmission routes of the disease; Characteristics of the condition; Incubation periods for the hepatitis viruses, A, E and D; Physiology and main functions of the liver; Steps in preventing virus infection.

  • Non-Organ-Specific Autoantibodies in Hepatitis C Virus Infection: Do They Matter? Boqdanos, Dimitrios-Petrou; Mieli-Verqani, Giorgina; Vergani, Diego // Clinical Infectious Diseases;2/15/2005, Vol. 40 Issue 4, p508 

    This article reports that hepatotropic viruses, such as hepatitis B virus and hepatitis C virus (HCV), can take up permanent residence in the liver and cause serious chronic disease. These viruses are noncytopathic--viral clearance is performed by the host immune response and is associated with...

  • Factors Associated with Interest in Initiating Treatment for Hepatitis C Virus (HCV) Infection among Young HCV-Infected Injection Drug Users. Strathdee, Steffanie A.; Latka, M.; Campbell, J.; O'Driscoll, P. T.; Golub, E. T.; Kapadia, F.; Pollini, R. A.; Garfein, R. S.; Thomas, D. L.; Hagan, H. // Clinical Infectious Diseases;4/15/2005 Supplement, Vol. 40, pS304 

    Objective. We sought to identify factors associated with interest in receiving therapy for hepatitis C virus (HCV) infection among HCV-infected injection drug users (IDUs) in 3 United States cities. Methods. IDUs aged 18-3 5 years who were HCV-infected and seronegative for human immunodeficiency...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics